**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 90155

**Manuscript Type:** EDITORIAL

**Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control**

Zhang KX *et al*. Cardioprotective mechanisms of SGLT2 inhibitors

Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun

**Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun,** Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China

**Author contributions:** All the authors contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Corresponding author: Xiao-Dong Sun, PhD, Chief Physician,** Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China. xiaodong.sun@wfmc.edu.cn

**Received:** November 25, 2023

**Revised:** December 14, 2023

**Accepted:** January 16, 2024

**Published online:** February 15, 2024

**Abstract**

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a pivotal intervention in diabetes management, offering significant cardiovascular benefits. Empagliflozin, in particular, has demonstrated cardioprotective effects beyond its glucose-lowering action, reducing heart failure hospitalizations and improving cardiac function. Of note, the cardioprotective mechanisms appear to be independent of glucose lowering, possibly mediated through several mechanisms involving shifts in cardiac metabolism and anti-fibrotic, anti-inflammatory, and anti-oxidative pathways. This editorial summarizes the multifaceted cardiovascular advantages of SGLT2 inhibitors, highlighting the need for further research to elucidate their full therapeutic potential in cardiac care.

**Key Words:** Diabetes; Sodium-glucose cotransporter-2; Cardiovascular diseases; Empagliflozin

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Zhang KX, Kan CX, Han F, Zhang JW, Sun XD. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. *World J Diabetes* 2024; 15(2): 137-141

**URL**: https://www.wjgnet.com/1948-9358/full/v15/i2/137.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v15.i2.137

**Core Tip:** Sodium-glucose cotransporter-2 inhibitors like empagliflozin offer cardioprotective benefits that extend beyond blood glucose control, improving heart function and reducing failure-related hospitalizations. Ongoing research is essential to elucidate the underlying mechanisms, potentially revolutionizing heart failure treatment across various patient profiles.

**INTRODUCTION**

The global increase in diabetes represents a significant public health challenge and is closely associated with an increased risk for cardiovascular diseases (CVD)[1]. The lack of specific treatments to prevent its progression has left a significant gap in therapeutic strategies. Consequently, there is an urgent need for novel approaches to prevent and manage diabetes-related cardiac complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (*e.g.*, empagliflozin), primarily known for their glucose-lowering capability, have emerged as unexpected protective agents against CVD in patients with diabetes. SGLT2 inhibitors may have beneficial effects on heart failure, including cases with dilated cardiomyopathy, by improving cardiac function and reducing hospitalization rates for heart failure[2]. However, the unresolved cardioprotective mechanisms of these inhibitors have stimulated considerable scientific interest. The study by Li *et al*[3] provides an interesting insight into the molecular dynamics through which empagliflozin may exert its therapeutic effects on the diabetic heart.

Clinical trials have demonstrated that SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure and cardiovascular mortality. Notably, the DAPA-HF and EMPEROR-Reduced trials highlighted the positive effects of SGLT2 inhibition in patients with heart failure with a reduced ejection fraction, including those with and without diabetes[4-10]. A comprehensive meta-analysis further reinforced these findings, indicating that SGLT2 inhibitors decrease the risk of cardiovascular mortality or first hospitalization for heart failure across a broad spectrum of left ventricular ejection fractions[2,4]. Additionally, a meta-analysis involving over 21000 participants revealed consistent reductions in the risk of composite cardiovascular mortality or hospitalization for heart failure, as well as all-cause mortality[11]. Evidence from clinical studies also indicated that SGLT2 inhibitors can improve diastolic function, particularly in heart failure with a preserved ejection fraction, a condition commonly observed in diabetic heart disease[12].

Animal studies have similarly provided evidence to support the cardioprotective role of SGLT2 inhibitors. A meta-analysis of preclinical animal models found that SGLT2 inhibitors reduced myocardial infarct size independent of diabetes, indicating a potential for broad cardioprotective applications beyond glucose-lowering effects[13]. Our studies demonstrated that empagliflozin could also alleviate obesity-related cardiac dysfunction and attenuate ischemia/reperfusion injury[14,15]. These studies provided evidence that SGLT2 inhibitors could benefit a wide population of heart failure patients, not just those with a reduced ejection fraction.

On the basis of the experimental data provided by Li *et al*[3]*,* empagliflozin treatment displays therapeutic potential in mitigating diabetic cardiomyopathy in db/db mice. The treatment improved cardiac function, reduces myocardial apoptosis, and beneficially modulates signaling pathways associated with cardiac health, such as increased adenosine monophosphate-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) protein phosphorylation and decreased myosin phosphatase target subunit 1 phosphorylation. Furthermore, *in vitro* studies supported these findings, demonstrating that empagliflozin protects cardiomyocytes from high-glucose-induced mitochondrial damage, oxidative stress, and apoptosis, effects that were partly reversed by the addition of compound C, an AMPK inhibitor. The results were corroborated by the use of Rho kinase inhibitors and PGC-1α overexpression, which further validates the role of these pathways in cardiac protection. Interestingly, no SGLT2 protein expression was detected in cardiomyocytes, suggesting that the cardioprotective effects of empagliflozin may be independent of its glucose-lowering action and possibly mediated by AMPK/PGC-1α pathways. This indicates a potential non-glycemic beneficial effect of SGLT2 inhibitors on cardiac function in the context of diabetes, meriting further investigation. This study highlights novel mechanisms regarding the effectiveness of SGLT2 inhibitors in treating diabetic cardiomyopathy.

SGLT2 inhibitors, beyond their role in glucose excretion, confer cardiac protection through several mechanisms[16,17] (Figure 1). Primarily, they act as mild diuretics, which reduce cardiac preload and afterload by promoting natriuresis and osmotic diuresis, thereby lessening the cardiac load[18]. They also beneficially shift cardiac metabolism away from fatty acid oxidation, which is less oxygen-efficient, towards glucose utilization and potentially towards ketone body utilization, thus improving the heart’s energy efficiency[19]. These drugs may also protect against cardiac fibrosis by several means. They reduce hyperglycemia-related advanced glycation end-products, downregulate transforming growth factor-beta, and inhibit the cardiac sodium-hydrogen exchanger, which together help to prevent hypertrophy and fibrosis[20,21].

Moreover, SGLT2 inhibitors contribute to reducing arrhythmia risks and modulate ion homeostasis within the heart, suggesting a role in improving myocardial cell function and calcium handling[22]. Their cardioprotective effects extend to anti-inflammatory and antioxidant actions, because they diminish nuclear factor-kappaB activity and enhance antioxidant system activity (*e.g.*, Sestrin2, nuclear factor erythroid 2-related factor 2, heme oxygenase-1)[14,23]. This contributes to decreasing oxidative stress, another risk factor for heart failure. In addition, these drugs improve endothelial function and arterial compliance, partly through increased nitric oxide production, and affect the secretion of adipokines, which are involved in the pathophysiology of heart failure[24-26]. This endothelial protection was confirmed by studies showing that empagliflozin suppresses endothelial apoptosis and maintains capillarization through the protein kinase B/endothelial nitric oxide synthase/nitric oxide pathway, thereby enhancing heart performance[27]. Cai *et al*[28] further demonstrated that empagliflozin mitigates endothelial oxidative stress and inhibits mitochondrial apoptosis via the AMPK/unc-51 like autophagy activating kinase 1/FUN14 domain containing 1/mitophagy axis, thereby improving cardiac microvascular structure and endothelial function. SGLT2 inhibitors also induce protective autophagy and reduce apoptosis in cardiac cells, and they are being investigated for their potential effects on specific molecular pathways such as Sestrin2-AMPK, which are associated with heart failure management[14,23,29]. Overall, the multifaceted approach to SGLT2 inhibitors highlight their potential as a therapeutic strategy for cardiovascular health, with ongoing research continuing to elucidate their complex mechanisms and benefits.

Nevertheless, the exact mechanisms by which SGLT2 inhibitors exert their cardioprotective effects remain under investigation, and it is likely that multiple mechanisms act in concert. Perhaps the most striking finding was empagliflozin's effectiveness in the absence of SGLT2 expression in cardiomyocytes. This clearly demonstrated the diabetes-independent action of this drug, highlighting its potential as a targeted therapy for CVD. The cardioprotective effects observed in patients with heart failure, including those with CVD, have led to an expansion of the indications for SGLT2 inhibitors beyond diabetes to include the treatment of heart failure with a reduced ejection fraction, with ongoing research potentially further broadening their therapeutic applications. Despite these promising findings, further research is necessary to fully elucidate the extent to which these mechanisms contribute to the cardiovascular benefits of SGLT2 inhibitors, the understanding of which will enhance the clinical application of these agents and potentially lead to more targeted treatments for patients with diabetic heart disease.

**Conclusion**

SGLT2 inhibitors have become an essential therapeutic advancement in diabetes management due to their low risk of hypoglycemia and notable cardiovascular benefits. In addition to their glucose-lowering effects, SGLT2 inhibitors are recognized for their efficacy in treating heart failure through various non-glycemic mechanisms. These include hemodynamic changes and anti-inflammatory, anti-fibrotic, antioxidant, and metabolic effects, which together contribute to the cardiovascular advantages observed with SGLT2 inhibitor use. Further research is ongoing to fully understand the mechanisms through which these inhibitors exert their cardioprotective effects.

**REFERENCES**

1 **Zhang X**, Zhu J, Kim JH, Sumerlin TS, Feng Q, Yu J. Metabolic health and adiposity transitions and risks of type 2 diabetes and cardiovascular diseases: a systematic review and meta-analysis. *Diabetol Metab Syndr* 2023; **15**: 60 [PMID: 36973730 DOI: 10.1186/s13098-023-01025-w]

2 **Vaduganathan M**, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, McMurray JJV, Solomon SD. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet* 2022; **400**: 757-767 [PMID: 36041474 DOI: 10.1016/S0140-6736(22)01429-5]

3 **Li N**, Zhu Q, Li G, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably *via* activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. *World J Diabetes* 2023; **14**: 1862-1876 [DOI: 10.4239/wjd.v14.i12.1862]

4 **Zannad F**, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020; **396**: 819-829 [PMID: 32877652 DOI: 10.1016/S0140-6736(20)31824-9]

5 **Rossing P**, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes Endocrinol* 2022; **10**: 24-34 [PMID: 34856173 DOI: 10.1016/S2213-8587(21)00295-3]

6 **McMurray JJV**, Solomon SD, Docherty KF, Jhund PS. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. *Eur Heart J* 2021; **42**: 1199-1202 [PMID: 31898736 DOI: 10.1093/eurheartj/ehz916]

7 **Vaduganathan M**, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. *Lancet* 2020; **396**: 121-128 [PMID: 32446323 DOI: 10.1016/S0140-6736(20)30748-0]

8 **McMurray JJV**, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2019; **381**: 1995-2008 [PMID: 31535829 DOI: 10.1056/NEJMoa1911303]

9 **Packer M**, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med* 2020; **383**: 1413-1424 [PMID: 32865377 DOI: 10.1056/NEJMoa2022190]

10 **Verma S**, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. *Lancet Diabetes Endocrinol* 2022; **10**: 35-45 [PMID: 34861154 DOI: 10.1016/S2213-8587(21)00292-8]

11 **Zelniker TA**, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019; **393**: 31-39 [PMID: 30424892 DOI: 10.1016/S0140-6736(18)32590-X]

12 **Nassif ME**, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nat Med* 2021; **27**: 1954-1960 [PMID: 34711976 DOI: 10.1038/s41591-021-01536-x]

13 **Sayour AA**, Celeng C, Oláh A, Ruppert M, Merkely B, Radovits T. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis. *Diabetologia* 2021; **64**: 737-748 [PMID: 33483761 DOI: 10.1007/s00125-020-05359-2]

14 **Sun X**, Han F, Lu Q, Li X, Ren D, Zhang J, Han Y, Xiang YK, Li J. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice. *Diabetes* 2020; **69**: 1292-1305 [PMID: 32234722 DOI: 10.2337/db19-0991]

15 **Lu Q**, Liu J, Li X, Sun X, Zhang J, Ren D, Tong N, Li J. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. *Mol Cell Endocrinol* 2020; **501**: 110642 [PMID: 31759100 DOI: 10.1016/j.mce.2019.110642]

16 **Huang K**, Luo X, Liao B, Li G, Feng J. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. *Cardiovasc Diabetol* 2023; **22**: 86 [PMID: 37055837 DOI: 10.1186/s12933-023-01816-5]

17 **Li N**, Zhou H. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy. *Drug Des Devel Ther* 2020; **14**: 4775-4788 [PMID: 33192053 DOI: 10.2147/DDDT.S269514]

18 **Packer M**, Anker SD, Butler J, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. *JAMA Cardiol* 2017; **2**: 1025-1029 [PMID: 28768320 DOI: 10.1001/jamacardio.2017.2275]

19 **Yurista SR**, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. *Eur J Heart Fail* 2019; **21**: 862-873 [PMID: 31033127 DOI: 10.1002/ejhf.1473]

20 **Li C**, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. *Cardiovasc Diabetol* 2019; **18**: 15 [PMID: 30710997 DOI: 10.1186/s12933-019-0816-2]

21 **Uthman L**, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na(+)](c)/ROS-pathway in human endothelial cells. *Biomed Pharmacother* 2022; **146**: 112515 [PMID: 34896968 DOI: 10.1016/j.biopha.2021.112515]

22 **Cardoso R**, Graffunder FP, Ternes CMP, Fernandes A, Rocha AV, Fernandes G, Bhatt DL. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. *EClinicalMedicine* 2021; **36**: 100933 [PMID: 34308311 DOI: 10.1016/j.eclinm.2021.100933]

23 **Quagliariello V**, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. *Cardiovasc Diabetol* 2021; **20**: 150 [PMID: 34301253 DOI: 10.1186/s12933-021-01346-y]

24 **Ugusman A**, Kumar J, Aminuddin A. Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors. *Pharmacol Ther* 2021; **224**: 107832 [PMID: 33662450 DOI: 10.1016/j.pharmthera.2021.107832]

25 **Navodnik MP**, Janež A, Žuran I. The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus-ENDIS Study. *Pharmaceutics* 2023; **15** [PMID: 37514131 DOI: 10.3390/pharmaceutics15071945]

26 **Mone P**, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. *Hypertension* 2022; **79**: 1633-1643 [PMID: 35703100 DOI: 10.1161/HYPERTENSIONAHA.122.19586]

27 **Nakao M**, Shimizu I, Katsuumi G, Yoshida Y, Suda M, Hayashi Y, Ikegami R, Hsiao YT, Okuda S, Soga T, Minamino T. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. *Sci Rep* 2021; **11**: 18384 [PMID: 34526601 DOI: 10.1038/s41598-021-97787-2]

28 **Cai C**, Guo Z, Chang X, Li Z, Wu F, He J, Cao T, Wang K, Shi N, Zhou H, Toan S, Muid D, Tan Y. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. *Redox Biol* 2022; **52**: 102288 [PMID: 35325804 DOI: 10.1016/j.redox.2022.102288]

29 **Ala M**. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. *Endocrinology* 2021; **162** [PMID: 34343274 DOI: 10.1210/endocr/bqab157]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict-of-interests in preparing this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 25, 2023

**First decision:** December 12, 2023

**Article in press:** January 16, 2024

**Specialty type:** Endocrinology & metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Habte ML, Ethiopia; Horowitz M, Australia; Qureshi W, India; Yan LJ, United States **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Chen YX

**Figure Legends**



**Figure 1 The cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control.** SGLT2i: Sodium-glucose cotransporter-2 inhibitor; AMPK: Adenosine monophosphate-activated protein kinase; Akt: Protein kinase B; eNOS: Endothelial nitric oxide synthase; NO: Nitric oxide; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator-1alpha; ULK1: Unc-51 like autophagy activating kinase 1; FUNDC1: FUN14 domain containing 1.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**